arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Candel Therapeutics, Inc.

CADL
$11.28 ▼ -0.57 (-4.81%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Candel Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $836.2M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -16.8%
FCF / Share $-0.23
Trailing P/E
Price / Book 6.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.00K
— 0.0%
Net Income Profit after all expenses
$-38.91M
↓ -711.2%
FCF / Share Free cash flow per share
$-0.23
↑ +22.4%
Long-Term Debt Long-term obligations
$4.22M
↓ -37.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Financial Health
23
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters